info@seagull-health.com
SeagullHealth
search
Kineret(Anakinra)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Kineret(Anakinra) Instructions:Uses,Dosage, Side Effects
Kineret (Anakinra) is a biologic medication primarily used to manage autoimmune and inflammatory conditions, such as rheumatoid arthritis (RA), cryopyrin-associated periodic syndromes (CAPS), and deficiency of interleukin-1 receptor antagonist (DIRA). It works by inhibiting interleukin-1 (IL-1), a cytokine involved in inflammation, to reduce joint damage in RA and control severe inflammatory episodes in genetic disorders like NOMID and DIRA.
The drug is administered via subcutaneous injection, typically on a daily or alternate-day basis, depending on the clinical condition and renal function of the patient. Its efficacy in reducing inflammation and halting disease progression makes it a key treatment option in specific inflammatory disorders resistant to conventional therapies. However, close monitoring for side effects, including infections and hypersensitivity reactions, is recommended.
1. Kineret is indicated for the following conditions:Rheumatoid Arthritis (RA): Reduction in signs and symptoms, and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis in patients 18 years or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs).
2. Cryopyrin-Associated Periodic Syndromes (CAPS): Including treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
3. Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Treatment of patients with DIRA.
1. Rheumatoid Arthritis (RA):The recommended dose is 100 mg daily administered via subcutaneous injection. Patients with severe renal insufficiency or end-stage renal disease should receive a reduced dose of 100 mg every other day.
2. Cryopyrin-Associated Periodic Syndromes (CAPS):The recommended starting dose is 1-2 mg/kg daily for NOMID patients. The dose can be adjusted to a maximum of 8 mg/kg daily to control inflammation. In patients with severe renal insufficiency or end-stage renal disease, consider administering the prescribed dose every other day.
3. Deficiency of Interleukin-1 Receptor Antagonist (DIRA):The recommended starting dose is 1-2 mg/kg daily, adjustable to a maximum of 8 mg/kg daily. In patients with severe renal insufficiency or end-stage renal disease, consider administering the dose every other day.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
